IQSEC1 Knockout HEK293T Polyclonal Cells are a heterogeneous population of HEK293T cells engineered via CRISPR/Cas9-mediated gene disruption to ablate IQSEC1 function. This polyclonal knockout model offers a robust tool for investigating loss-of-function effects of the ARF guanine nucleotide exchange factor IQSEC1, a pivotal regulator of endosomal trafficking and actin dynamics. The polyclonal format captures diverse editing events, minimizing clonal biases and enabling population-level analyses.
HEK293T cells are adherent human embryonic kidney epithelial cells stably expressing the SV40 large T antigen, enabling episomal plasmid replication. This line is a mainstay for transient protein expression, viral production, and functional genomic screens due to its high transfectability and well-characterized biology, making it an ideal host for gene disruption studies focused on intracellular trafficking.
IQSEC1 functions as a GEF for ARF GTPases, primarily ARF6 and ARF1. It is activated by integrin engagement and PIP2, and interacts with activated integrins and ARF-GDP. IQSEC1 catalyzes ARF6-GTP formation, which stimulates PIP5K to generate PIP2, promoting actin remodeling. Additionally, IQSEC1 activates ARF1 to recruit AP-1 and clathrin for endosomal sorting. Downstream effectors include Rac1 and PAK1, linking IQSEC1 to actin polymerization and focal adhesion dynamics. Thus, IQSEC1 sits at the nexus of two pathways: IQSEC1??ARF6??PIP5K??PIP2??actin remodeling and IQSEC1??ARF1??AP-1/clathrin??endosomal sorting.
In HEK293T cells, IQSEC1 directs the recycling of ??1 integrins from endosomes to the plasma membrane. Knockout of IQSEC1 disrupts this process, reducing surface integrin levels and impairing focal adhesion turnover, cell adhesion, and migration. This phenotype reflects altered ARF6-GTP loading and diminished PAK1/AKT signaling. The model provides a precise background to dissect IQSEC1-dependent coordination of endosomal recycling and actin dynamics, relevant to cancer metastasis and neurodevelopmental disorders like X-linked intellectual disability.
Key applications include monitoring ARF6-GTP levels by pull-down, immunofluorescence-based integrin recycling assays, transwell migration/invasion assays, and phospho-signaling analysis of PAK1 and AKT. Co-immunoprecipitation can assess altered interactions with PIP5K or ??1 integrin, while flow cytometry quantifies surface integrin levels. Functional complementation studies can rescue the knockout phenotype. For additional information or support, contact Ascent Research.
